This Week in Cell and Gene Therapy: 11 New Developments to Know (September 12, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Kite Pharma, a Gilead Company based in Santa Monica, CA, has announced that the European Commission (EC) has granted approval for its chimeric antigen receptor (CAR) T cell therapy Tecartus […]

This Week in Cell and Gene Therapy: 8 New Developments to Know (August 22, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Prescient Therapeutics, a clinical stage oncology company based in Melbourne, Australia, has signed a five-year manufacturing agreement with Q-Gen Cell Therapeutics, a specialist cell therapy manufacturer based at the QIMR […]

This Week in Cell and Gene Therapy: 10 New Developments to Know (August 9, 2022)

This Week in Cell and Gene Therapy: 10 New Developments to Know (July 11, 2022)

This Week in Cell and Gene Therapy: 14 New Developments to Know (June 27, 2022)

This Week in Cell and Gene Therapy: 12 New Developments to Know (June 13, 2022)

This Week in Cell and Gene Therapy: 14 New Developments to Know (May 23, 2022)

This week in Cell and Gene Therapy: 14 New Developments to Know (May 9, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. The U.S. FDA has lifted clinical holds on two Phase III clinical studies evaluating gene therapies being developed by Pfizer, based in New York, NY. On April 28th, Pfizer announced […]

12 Recent Developments in Cell and Gene Therapy as of April 22, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. In public offering news, Massachusetts-based Selecta Biosciences has announced a $38.7 million public offering to continue developing ImmTOR, its antigen-specific immune tolerance platform. Leading the private financing news, Cambridge-based cell […]

13 Recent Developments in Cell and Gene Therapy as of April 8, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Bristol Myers Squibb, based in New York, NY, has announced that the European Commission (EC) has granted Marketing Authorization for Breyanzi (lisocabtagene maraleucel; liso-cel), its CD19-targeted chimeric antigen receptor (CAR)-T […]